Loading data for HALO — first visit, this takes a few seconds.

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS: HALO · Real-Time Price · USD

105.35

-1.57 (-1.47%)

At close: Sep 01, 2026, 1:35 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	100.51
Market Cap	12.3B
Revenue (ttm)	1.66B
Net Income (ttm)	414M
	0.85
	3.41
	31.69
	10.4
P/B (ttm)	85.82
P/S (ttm)	7.37
Earnings Date	Nov 2, 2026

Ask	111.99
Volume	1,681,619
Avg. Volume (20D)	2,014,948
Open	106.45
Previous Close	106.92
Day's Range	104.70 - 106.81
52-Week Range	61.23 - 109.66
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluid...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 16, 2004

Employees 423

Stock Exchange NasdaqGS

Ticker Symbol HALO

Website https://halozyme.com

Full Company Profile

Financial Performance

In 2025, Halozyme Therapeutics's revenue was 1.4B, an increase of 37.55% compared to the previous year's 1.02B. Earnings were 316.89M, a decrease of -28.64%.

Financial Statements

Earnings Surprise

Halozyme Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $481M misses estimates by $0, with 47.67% YoY growth.
EPS of 2.28 exceeds estimates by 0.46, with 48.05% YoY growth.

Next Earnings Release

Halozyme Therapeutics, Inc. is scheduled to release its earnings on Nov 2, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 weeks ago · StockStory

The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call

Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance to surging royalty revenue and a wave of ne...

2 weeks ago · Insider Monkey

Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033...